CN1256940C - Compound Chinese medicine notoginseng dripping pills and its prepn process - Google Patents
Compound Chinese medicine notoginseng dripping pills and its prepn process Download PDFInfo
- Publication number
- CN1256940C CN1256940C CN 02103920 CN02103920A CN1256940C CN 1256940 C CN1256940 C CN 1256940C CN 02103920 CN02103920 CN 02103920 CN 02103920 A CN02103920 A CN 02103920A CN 1256940 C CN1256940 C CN 1256940C
- Authority
- CN
- China
- Prior art keywords
- group
- notoginseng
- blood
- radix
- dripping pills
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000006187 pill Substances 0.000 title claims abstract description 151
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 102
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 102
- 150000001875 compounds Chemical class 0.000 title claims abstract description 84
- 239000003814 drug Substances 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title description 4
- 230000008569 process Effects 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims abstract description 5
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 11
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 229940057995 liquid paraffin Drugs 0.000 claims description 6
- 208000032843 Hemorrhage Diseases 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 231100000216 vascular lesion Toxicity 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002826 coolant Substances 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000009101 diabetic angiopathy Diseases 0.000 abstract description 3
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 abstract description 3
- 231100000915 pathological change Toxicity 0.000 abstract description 2
- 230000036285 pathological change Effects 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241001530126 Scrophularia Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 88
- 239000008280 blood Substances 0.000 description 87
- 241000700159 Rattus Species 0.000 description 37
- 229940079593 drug Drugs 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 20
- 208000007536 Thrombosis Diseases 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 230000017531 blood circulation Effects 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 14
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 13
- 206010053567 Coagulopathies Diseases 0.000 description 11
- 229920002307 Dextran Polymers 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000035602 clotting Effects 0.000 description 11
- 230000004089 microcirculation Effects 0.000 description 11
- 238000004062 sedimentation Methods 0.000 description 11
- 108010049003 Fibrinogen Proteins 0.000 description 9
- 102000008946 Fibrinogen Human genes 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 229940012952 fibrinogen Drugs 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 238000011552 rat model Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 208000017442 Retinal disease Diseases 0.000 description 7
- 206010038923 Retinopathy Diseases 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 210000002565 arteriole Anatomy 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- 150000002338 glycosides Chemical class 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 208000004644 retinal vein occlusion Diseases 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 5
- 206010041956 Stasis syndrome Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 208000005634 blind loop syndrome Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 5
- 229950009941 chloralose Drugs 0.000 description 5
- 210000003191 femoral vein Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 210000000264 venule Anatomy 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 201000005667 central retinal vein occlusion Diseases 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002275 pentobarbital sodium Drugs 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000002537 thrombolytic effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 241000545442 Radix Species 0.000 description 2
- 206010038491 Renal papillary necrosis Diseases 0.000 description 2
- 241000594182 Sarcophaga sigma Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960001008 heparin sodium Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000031354 Hyphema Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940086319 nattokinase Drugs 0.000 description 1
- 108010073682 nattokinase Proteins 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Group | Dosage (mg/kg) | Clotting time (s, x ± s) |
Dosage group drop pill small dose group in the heavy dose of group of the normal saline drop pill drop pill | Isometric(al) 240 168 117.6 | 313±66 411±61* 424±81* 472±134** |
Grouping | Drug dose (mg/1ml | The example number | Dissolution rate to every 80mg sludged blood | The ordering coefficient * of Friedman check |
) | (mg,x±s) | |||
Dosage group drop pill small dose group in the heavy dose of group of the normal saline drop pill drop pill | Isometric(al) 14 9.8 6.86 | 13 13 13 13 | 18.03±12.61 34.87±17.56 27.38±13.02 31.24±15.36 | 1.77 3.46 2.62 3.31 |
Grouping | Drug dose (g/kg) | The example number | Thrombus weight (mg, x ± s) |
Dosage group drop pill small dose group in the heavy dose of group of the normal saline drop pill drop pill | Isometric(al) 0.14 0.098 0.0686 | 10 10 10 10 | 14.31±3.61 11.08±3.32* 11.38±2.14*§ 11.48±2.89*§ |
Group | Dosage (20ul, mg/ml) | The example number | Platelet maximum agglutination rate (%) (x ± s) |
Dosage group drop pill small dose group in the heavy dose of group of the normal saline drop pill drop pill | Isometric(al) 14 9.8 6.86 | 14 14 14 14 | 38.2±12.6 37.5±7.0 37.3±9.2 39.8±11.2 |
Group | Dosage (g/Kg) | Number of animals | Platelet adhesion rate (%) | |
Before the administration | After the administration | |||
Dosage group drop pill small dose group in the heavy dose of group of the normal saline drop pill drop pill | Isometric(al) 0.1 0.07 0.049 | 5 5 5 5 | 39.28±12.55 35.90±9.88 38.18±5.59 44.50±6.49 | 39.36±14.82 23.68±5.66* 30.64±2.12* 37.20±7.51 |
Group | Drug dose (g/kg) | Different shear rate whole blood viscosity (mPas) | |||
1/S | 5/S | 30/S | 150/S | ||
Dosage group dripping pill small dose group in the heavy dose of group of the normal group physiological saline group dripping pill dripping pill | Isometric(al) NS isometric(al) 0.14 0.098 0.0686 | 14.24±2.35 18.28±4.17 ΔΔ 15.28±2.41 * 17.01±3.61 Δ 16.76±2.34 | 8.85±1.09 11.13±2.04 ΔΔ 9.30±1.35* * 10.04±1.72 9.85±1.20* | 6.72±0.67 8.37±1.34 ΔΔ 6.95±1.00* * 7.41±1.10* 7.19±0.80* * | 5.98±0.54 7.43±1.13Δ Δ 6.15±0.86** 6.49±0.89** 6.36±0.64** |
Group | Drug dose (g/kg) | Packed cell volume (L/L) | Reduction viscosity of blood | The low reduced viscosity of cutting of whole blood |
Dosage group dripping pill small dose group in the heavy dose of group of the normal group physiological saline group dripping pill dripping pill | Isometric(al) NS isometric(al) 0.14 0.098 0.0686 | 0.44±0.03 0.45±0.05 0.44±0.03 0.44±0.04 0.45±0.04 | 11.35±1.69 14.19±2.37Δ Δ 11.60±1.92** 12.46±1.32* 11.86±1.26** | 30.22±6.49 38.23±9.49Δ Δ 32.13±5.10 36.18±5.70Δ 34.77±3.43 |
Group | Drug dose (g/kg) | Erythrocyte sedimentation rate mm/h | The erythrocyte rigidity index | Erythrocyte aggregation index | ESR equation K value |
Dosage group dripping pill small dose group in the heavy dose of group of the normal group physiological saline group dripping pill dripping pill | Isometric(al) NS isometric(al) 0.14 0.098 0.0686 | 2.1±1.6 2.8±2.7 1.5±0.9 1.5±1.0 2.0±2.2 | 5.09±1.62 4.80±2.30 3.66±1.33 Δ 3.78±1.41 3.43±1.59 Δ | 2.37±0.23 2.45±0.31 2.48±0.16 2.60±0.23 Δ 2.63±0.19 Δ | 7±6 13±20 5±3 5±4 7±6 |
Group | Drug dose (g/kg) | Fibrinogen (g/L) | Plasma viscosity (mPas) 100/S | The maximum percentage rate (%) of assembling of platelet |
Dosage group dripping pill small dose group in the heavy dose of group of the normal group model group dripping pill dripping pill | Isometric(al) NS isometric(al) 0.14 0.098 0.0686 | 1.07±0.39 3.71±1.15ΔΔ 3.76±1.29ΔΔ 3.16±1.46ΔΔ 3.40±1.15ΔΔ | 1.90±0.30 2.61±1.02Δ 2.48±0.75Δ 2.56±0.68Δ 2.43±0.48 | 37.0±9.0 44.2±18.7 35.5±14.0 35.0±8.6 37.1±11.1 |
Group | Drug dose (g/kg) | Different shear rate whole blood viscosity (mPas) | |||
1/S | 5/S | 30/S | 150/S | ||
Normal group | Isometric(al) NS | 14.24±2.3 5 | 8.85±1.09 | 6.72±0.67 | 5.98±0.54 |
Dosage group dripping pill small dose group in the heavy dose of group of the physiological saline group dripping pill dripping pill | B isometric(al) 0.140 0.098 0.0686 | 22.96±6.5 9 20.66±3.6 1 21.27±4.7 1 17.34±4.5 5** | 13.53±3.42 12.53±2.15 12.68±2.75 10.52±2.59 ** | 9.91±2.31 9.36±1.68 9.36±2.07 7.86±1.88* | 8.67±1.96 8.28±1.54 8.23±1.86 6.94±1.65* |
Group | Drug dose (g/kg) | Packed cell volume (L/L) | Reduction viscosity of blood | The low reduced viscosity of cutting of whole blood |
Dosage group dripping pill small dose group in the heavy dose of group of the normal group physiological saline group dripping pill dripping pill | Isometric(al) NS isometric(al) 0.140 0.98 0.686 | 0.44±0.03 0.53±0.05 0.53±0.07 0.57±0.06 0.51±0.08 | 11.35±1.69 14.73±4.15Δ Δ 13.63±2.03 12.64±2.30 11.70±3.21* | 30.22±6.49 42.38±14.79 ΔΔ 36.91±5.05 35.52±6.02 31.98±8.01** |
Group | Drug dose (g/kg) | Erythrocyte sedimentation rate mm/h | The erythrocyte rigidity index | Erythrocyte aggregation index | ESR equation K value |
Normal group normal saline group | Isometric(al) NS isometric(al) | 2.1±1.6 3.0±3.0 | 5.09±1.62 5.21±2.88 | 2.37±0.23 2.63±0.29 | 7±6 18±19 |
Dosage group drop pill small dose group in the heavy dose of group of the drop pill drop pill | 0.140 0.98 0.686 | 2.2±2.0 2.9±2.7 3.9±5.3 | 4.40±1.87 3.92±1.43 3.16±1.53* | 2.51±0.30 2.60±0.29 2.49±0.24 | 14±12 22±19 20±21 |
Group | Drug dose (g/kg) | Fibrinogen (g/L) | Plasma viscosity (mPas) 100/S |
Dosage group dripping pill small dose group in the heavy dose of group of the normal group physiological saline group dripping pill dripping pill | Isometric(al) NS isometric(al) 0.140 0.98 0.686 | 1.07±0.39 0.61±0.14ΔΔ 0.65±0.19 0.69±0.41 0.79±0.35 | 1.90±0.30 2.58±0.96 2.65±0.88 2.70±0.84 2.76±0.70 |
Grouping | Drug dose (g/kg) | Normally | Give 15min behind the dextran | After the administration 6 ' |
Dosage group drop pill small dose group in the heavy dose of group of the normal saline group drop pill drop pill | Isometric(al) 0.140 0.98 0.686 | 27.13±1.25 27.38±1.19 27.38±1.30 27.00±1.51 | 27.38±1.77 27.63±1.60 27.75±1.75 27.50±1.69 | 27.25±1.83 27.63±1.41 27.63±1.41 27.38±1.41 |
Grouping | Drug dose (g/kg) | Normally | Give 15min behind the dextran | After the administration 60 ' |
Dosage group drop pill small dose group in the heavy dose of group of the normal saline group drop pill drop pill | Isometric(al) 0.140 0.98 0.686 | 4.86±0.34 4.94±0.33 4.93±0.42 4.83±0.54 | 0.61±0.21 0.64±0.18 0.65±0.21 0.66±0.24 | 1.25±0.47*# 1.39±0.45*# 1.44±0.52*# 1.44±0.51*# |
Grouping | Drug dose (g/kg) | Normally | Give 15min behind the dextran | After the administration 60 ' |
Dosage drop pill small dose group in the heavy dose of drop pill of normal saline group drop pill | Isometric(al) 0.140 0.98 0.686 | 1749.41±64.71 1810.09±72.28 1803.21±75.74 1717.90± | 219.14±58.74 235.60±45.55 239.28±57.28 240.95±70.97 | 440.52± 508.56± 526.64± 517.25± |
Grouping | Normally | Give 15min behind the dextran | After the administration 60 ' |
Dosage drop pill small dose group in the heavy dose of drop pill of normal saline group drop pill | 27.75±1.04 27.50±1.20 27.63±1.06 27.63±1.19 | 28.63±1.19 28.50±1.51 28.63±1.06 28.88±1.46 | 28.13±1.13 28.25±1.16 28.25±1.04 28.25±1.49 |
Grouping | Drug dose (g/kg) | Normally | Give 15min behind the dextran | After the administration 60 ' |
Dosage group drop pill small dose group in the heavy dose of group of the model group drop pill drop pill | Isometric(al) 0.140 0.98 0.686 | 1.88±0.28 1.93±0.27 1.91±0.24 1.90±0.34 | 0.16±0.08 0.18±0.07 0.18±0.09 0.20±0.13 | 0.45±0.10*# 0.52±0.15*# 0.51±0.14*# 0.53±1.49*# |
Grouping | Drug dose (g/kg) | Normally | Give 15min behind the dextran | After the administration 60 ' |
Dosage group drop pill small dose group in the heavy dose of group of the model group drop pill drop pill | Isometric(al) 0.140 0.98 0.686 | 704.03±68.32 709.39±56.69 711.71±48.38 703.45±71.03 | 63.82±27.13 71.24±25.65 71.79±32.03 78.64±44.08 | 171.12± 200.34± 199.55± 202.60± |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02103920 CN1256940C (en) | 2002-02-07 | 2002-02-07 | Compound Chinese medicine notoginseng dripping pills and its prepn process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02103920 CN1256940C (en) | 2002-02-07 | 2002-02-07 | Compound Chinese medicine notoginseng dripping pills and its prepn process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1436549A CN1436549A (en) | 2003-08-20 |
CN1256940C true CN1256940C (en) | 2006-05-24 |
Family
ID=27627938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02103920 Expired - Lifetime CN1256940C (en) | 2002-02-07 | 2002-02-07 | Compound Chinese medicine notoginseng dripping pills and its prepn process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1256940C (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322871C (en) * | 2003-11-07 | 2007-06-27 | 唐俊琪 | Preparation of compound pseudo-ginseng drop pellets for treating traumatologic disease |
CN1325042C (en) * | 2004-11-26 | 2007-07-11 | 北京正大绿洲医药科技有限公司 | Oral drop pills for treating bronchitis and preparation method thereof |
CN1325043C (en) * | 2004-11-26 | 2007-07-11 | 北京正大绿洲医药科技有限公司 | Sweet wormwood oil drop pills and preparation method thereof |
CN1297254C (en) * | 2004-11-26 | 2007-01-31 | 北京正大绿洲医药科技有限公司 | Drop pills containing bear gall and tendril-leaved fritillary bulb and preparation method thereof |
CN1297256C (en) * | 2004-11-30 | 2007-01-31 | 北京正大绿洲医药科技有限公司 | Oral drop pills for treating coronary disease and preparation method thereof |
CN1307976C (en) * | 2004-11-30 | 2007-04-04 | 北京正大绿洲医药科技有限公司 | Thorax comforting drop pills for treating cardiopathy and preparation method thereof |
CN1297255C (en) * | 2004-11-30 | 2007-01-31 | 北京正大绿洲医药科技有限公司 | Dripping pills for treating high blood fat and its preparing method |
CN102895559A (en) * | 2012-10-30 | 2013-01-30 | 唐雯 | Chinese medicinal preparation for treating central serous chorioretinopathy |
CN104666816A (en) * | 2015-02-12 | 2015-06-03 | 张宏国 | Traditional Chinese medicine preparation for treating retinal arterial obstruction |
CN106994150A (en) * | 2017-04-22 | 2017-08-01 | 张挺 | A kind of Chinese medicine dripping pills for treating blood vessel venereal disease and preparation method thereof |
-
2002
- 2002-02-07 CN CN 02103920 patent/CN1256940C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1436549A (en) | 2003-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102908583B (en) | Traditional Chinese medicine composition for treating chest stuffiness and pains as well as preparation method, quality detection method and application of composition | |
CN1247241C (en) | Liuwei Dihuang dripping pills and its preparation | |
CN1256940C (en) | Compound Chinese medicine notoginseng dripping pills and its prepn process | |
CN1327876C (en) | Chinese drugs compositions for treating diabetes and its complications | |
CN1762401A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
CN1164264C (en) | Dispersed general arasaponin tablet and its prepn and application | |
CN101700265B (en) | Application of notoginseng and extract thereof in preparing medicament for curing and/or preventing diabetic microangiopathies | |
CN1857385B (en) | Medicine composition for treating cervical spondylosis and its preparing method | |
CN1939383B (en) | Use of redback christmashush in preparing medicine for hepatitis B | |
CN1935178A (en) | Ginkgo leaf extract and barrenwort extract composition | |
CN1698820A (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
CN1692936A (en) | Large specification Liuweidihang dripping pills contg. glutinous rehmannia and five other herb medicines, and its prepn. method | |
CN1216618C (en) | A TCM compound recipe notoginseng capsule and method for preparing the same | |
CN1634476A (en) | Chinese ephedra and almond containing cough stopping dripping pills and its preparing process | |
CN1223366C (en) | Hemostat and its usage | |
CN1268319C (en) | Rhodiola sacra injection and its preparation | |
CN1582946B (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels | |
CN105147923B (en) | A kind of Chinese medicine composition for treating coronary heart disease and preparation method thereof | |
CN104173504B (en) | A kind of Chinese medicine capsules treating diabetic retinopathy and application thereof | |
CN104161849B (en) | A kind of Chinese medicinal tablet treating diabetic retinopathy and application thereof | |
CN100486598C (en) | Bupleurum root asarum herb dripping pill and its preparing method | |
CN1476838A (en) | High-activity ginkgo leaf extract preparation and application | |
CN100531740C (en) | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels | |
CN101628022A (en) | Safflower dripping pill and preparation method thereof | |
CN1315467C (en) | liver-clearing dropping pill for treating hepatitis and its preparing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Huang Haibo Document name: Invalidation case notification |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: GUANGDONG ZHONGSHENG PHARMACEUTICAL Co.,Ltd. Assignor: Huang Haibo Contract fulfillment period: 2008.8.30 to 2022.2.6 Contract record no.: 2008440000224 Denomination of invention: Compound Chinese medicine notoginseng dripping pills and its prepn process Granted publication date: 20060524 License type: General permission Record date: 20080904 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: COMMON LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.8.30 TO 2022.2.6 Name of requester: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD. Effective date: 20080904 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: GUANGDONG SHUNFENG PHARMACEUTICAL CO.,LTD. Assignor: Huang Haibo Contract fulfillment period: 2008.9.5 to 2011.9.4 Contract record no.: 2008440000290 Denomination of invention: Compound Chinese medicine notoginseng dripping pills and its prepn process Granted publication date: 20060524 License type: General permission Record date: 20081024 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: COMMON LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.5 TO 2011.9.4; CHANGE OF CONTRACT Name of requester: GUANGDONG SHUNFENG PHARMACEUTICAL CO., LTD. Effective date: 20081024 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20030820 Assignee: GUANGZHOU WEISIBAO PHARMACEUTICAL Co.,Ltd. Assignor: Huang Haibo Contract record no.: 2014440000020 Denomination of invention: Compound Chinese medicine notoginseng dripping pills and its prepn process Granted publication date: 20060524 License type: Common License Record date: 20140122 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170706 Address after: 510300, 704, building 211, 157 southeast of grand Haizhuqu District, Xingang West Road, Guangzhou, Guangdong Co-patentee after: GUANGZHOU WEISIBAO PHARMACEUTICAL Co.,Ltd. Patentee after: Huang Haibo Address before: West Lake road Guangzhou city Guangdong province 510030 Silver Lake No. 38 building 11H Patentee before: Huang Haibo |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20060524 |
|
CX01 | Expiry of patent term | ||
DD01 | Delivery of document by public notice |
Addressee: Patent of Guangzhou WeiSiBao Pharmaceutical Co.,Ltd. The person in charge Document name: Notice of expiration and termination of patent right |
|
DD01 | Delivery of document by public notice |